Novo Nordisk CEO says he’s confident about Wegovy supply, next-generation weight loss drugs


 It's been a rocky few months for Novo Nordisk

Prescription data from IQVIA suggests Novo's obesity  King88bet Login drug Wegovy is losing ground to pesaing Zepbound from Eli Lilly

. Wegovy's potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo's stok has fallen more than 20% over the last year, and people feared things would get even worse when the company released fourth-quarter earnings and its 2025 outlook on Wednesday.


Instead, Novo beat fourth-quarter expectations and provided a sales growth forecast between 16% and 24% - in line with the 20% Wall Street was looking for. Novo's stok rose more than 4% on Wednesday.


In an interviu with CNBC, Novo Chief Executive King88bet Slot  Officer Lars Fruergaard Jorgensen brushed off concerns that Novo is falling behind Lilly.


"We are quite confident that as we move into the year and we'll be supplying more and more of the starter doses, we can see a nice tahap up in our volume and serving more and more patients," Jorgensen said. "And the guidance we have given for this year, you can say, testifies to an underlying significant ramp in our business. So we're quite confident both in the permintaan in the pasar and also our ability to suplai and compete in that pasar."


People taking Wegovy start off on the  King88bet Tergacor  lowest dose - or the starter dose - then work their way up to stronger formulations so their bodies can get used to the drug. At times, Novo has limited the amount of starter doses it shipped because it struggled to make enough of the drug and wanted to make sure people who were already on the medication could stay on it.


Novo's 2025 sales guidance implies a 30% increase in the number of patients taking one of the company's GLP-1 drugs, such as Ozempic, the company said on its earnings call.


The company also tried to reassure investors about CagriSema's efekiveness. Jorgensen said some people lost weight very quickly, and another grup lost weight continuously, showing no sign of stopping by the time the trial ended, so they might need longer treatment.


"I'm very confident in the potency of the biology we have here," he said.


People are watching an earlier-stage treatment - amycretin - even closer. That experimental drug recently showed promising results in a phase 1b/2a trial.


Jorgensen said Novo is talking to the FDA about possibly moving straight to a phase three trial.

Postingan populer dari blog ini

President Emmanuel Macron's plans to raise the retirement age from 62 to 64

Defenders of Qatar

Elusive anti-atoms